<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT931-6908</title>
	</head>
	<body>
		<main>
			<p>930226 FT  26 FEB 93 / World Stock Markets (America): US blue chips cling to their recent gains Wall Street BLUE CHIP stocks clung to their recent gains in the afternoon, with the help of programme-driven buying, while the the Nasdaq market held its ground through the day in spite of a sell-off in biotechnology bellwether company Amgen, reports Karen Zagor in New York. The Dow Jones Industrial Average closed 8.65 higher 3,365.15, after falling more than 10 points in morning trading. The more broadly based Standard&amp;Poor's 500 was up 1.69 at 442.56, while the Amex composite gained 2.02 at 405.43, and the Nasdaq composite added 4.61 to 667.07. Trading volume on the NYSE was more than 254m shares. Rises outnumbered declines by 1,063 to 804. The mixed tone of the market reflected continuing investor uneasiness about the Clinton administration's economic policy. Drug company stocks, which recovered lost ground at mid-week, once more turned lower yesterday. Merck was off Dollars  1/8 at Dollars 38 3/8 , Bristol-Myers Squibb lost Dollars  1/4 to Dollars 57 1/8 , and Pfizer eased Dollars  3/8 to Dollars 57 but Glaxo Holdings ADRs rose Dollars 1/8 to Dollars 18 3/4 . Among active NYSE stocks, Philip Morris dropped Dollars  3/8 to Dollars 66, Chrysler firmed Dollars  1/4 to Dollars 38 7/8 , Eastman Kodak rose Dollars 2 5/8 to Dollars 53 and AT&amp;T was Dollars  1/4 higher at Dollars 56 3/8 . Office Depot climbed Dollars  7/8 to Dollars 30 1/8 after Merrill Lynch increased its near-term rating on the stock from 'neutral' to above average. In Nasdaq trading, Amgen tumbled Dollars 9 1/4 to Dollars 37 in very heavy trading after the biotechnology company warned investors to expect disappointing first quarter earnings on the back of slower-than-expec ted sales of its important Neupogen cancer drug. Other biotechnology issues also moved lower including Chiron, off Dollars 1/2 at Dollars 48 3/4 and Synergen, down Dollars  1/4 at Dollars 14 3/4 . Cytogen fell Dollars  3/4 to Dollars 14 after Merrill Lynch downgraded its rating on the stock from 'buy' to 'near-term above average'. Nasdaq trading, however, was dominated by improving technology stocks. Intel added Dollars  1/4 to Dollars 118, Microsoft firmed Dollars  1/2 to Dollars 84 3/8 and Lotus Development rose Dollars  7/8 to Dollars 26 1/4 . Dell Computer regained some ground yesterday. The stock rose Dollars 2 1/2 to Dollars 32 5/8 . Canada TORONTO stocks ended a four-day winning streak with a mixed performance in extremely active trading. Based on preliminary figures, the 300 composite index fell 5.81 points, or 0.17 per cent, to 3,459.94, but advances outnumbered declines 353 to 273. Volume fell to 54.60m shares from 57.79m shares but the Wednesday total was boosted by a block of 9m Petro-Canada shares. Trading value was CDollars 492m compared with CDollars 549.6m.</p>
		</main>
</body></html>
            